Literature DB >> 8160471

Complete androgen blockade for metastatic prostate cancer.

J C Presti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8160471      PMCID： PMC1022329     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  4 in total

1.  Total androgen ablation: Canadian experience.

Authors:  G Béland; M Elhilali; Y Fradet; B Laroche; E W Ramsey; J Trachtenberg; P M Venner; H D Tewari
Journal:  Urol Clin North Am       Date:  1991-02       Impact factor: 2.241

2.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Authors:  E D Crawford; M A Eisenberger; D G McLeod; J T Spaulding; R Benson; F A Dorr; B A Blumenstein; M A Davis; P J Goodman
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

3.  Total androgen ablation: European experience. The EORTC GU Group.

Authors:  L Denis; P Smith; J L Carneiro de Moura; D Newling; A Bono; F Keuppens; C Mahler; M Robinson; R Sylvester; M De Pauw
Journal:  Urol Clin North Am       Date:  1991-02       Impact factor: 2.241

4.  Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.

Authors:  R A Janknegt; C C Abbou; R Bartoletti; L Bernstein-Hahn; B Bracken; J M Brisset; F C Da Silva; G Chisholm; E D Crawford; F M Debruyne
Journal:  J Urol       Date:  1993-01       Impact factor: 7.450
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.